Loading
companiesCompany
AbClon
AbClon is a South Korean antibody and cell-therapy company whose CD19 CAR-T AT101 uses a newly discovered antibody binder and has shown high response rates in relapsed B-cell lymphoma.
Also called: AbClon Inc.앱클론KOSDAQ:174900
Overview
AbClon, listed on KOSDAQ, discovers antibodies against novel epitopes and develops them as therapeutics and CAR-T cells. AT101 is an autologous CD19 CAR-T built on the h1218 antibody, which binds a different epitope of CD19 from the FMC63 binder used in approved products; a phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma reported complete responses in most patients at the higher doses and a phase 2 trial is under way in Korea. AbClon also develops the HER2 antibody AC101 and a switchable CAR-T platform.
Headquarters
Seoul, KR
Scorecard
All companies#297of 1244 companies, score 14
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +9
0 approved, 0 in phase 3, 1 earlier, 1 targets, 22 registry studies. Formula on the scorecards page.
Type
Cell therapy · KOSDAQ:174900
Stage
Public
Website
Founded
2010
Phase 2CAR-T cell therapy
AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.
drugs
Phase 2CAR-T cell therapy